Eli Lilly and Co., of Indianapolis, said the randomized, double-blind, global phase III REVEL study of ramucirumab in combination with chemotherapy in second-line non-small-cell lung cancer (NSCLC) showed a statistically significant improvement in the primary endpoint of overall survival (OS) in the ramucirumab-plus-docetaxel arm compared to the control arm of placebo plus docetaxel.